Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
In the last 90 days, Vir Biotechnology, Inc. insiders filed 0 open-market purchases and 1 sale; 237 institutions reported holding it in 13F filings for Q2 2026, worth $1.49B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $2.25B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $41.9K in total
- 1
- 13F holdersQ2 2026, −11 vs. previous quarter
- 237
- 13F valueReported value at the end of Q2 2026
- $1.49B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $68.6M
- −7.6% year over year
- Net income, FY2025
- -$438.0M
- No comparable prior period
- Free cash flow, FY2025
- -$396.6M
- No comparable prior period
- Revenue, Q3 FY2026
- -$188.0K
- −178.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $438.0M (638.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 16.9M
- Shares sold short
- Change
- +637.7K
- +3.9% vs. previous
- Days to cover
- 11.86
- At average daily volume
Superinvestors holding VIR, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VIR at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vir Biotechnology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)2:56 PM ET | Nov 2-3 | 2 days | de Verneuil VaninaEVP, General Counsel, Corp Sec | SSale | −3.75K | $11.18 | −$41.9K | −3.3%110.2K after | 2 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Napolitano JanetDirector | SSale | −3.20K | $9.45 | −$30.2K | −13.1%21.2K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Sabatini BrentSVP, Chief Accounting Officer | SSale | −379 | $9.45 | −$3.58K | −0.6%61.9K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Sato Vicki LDirector | SSale | −22.0K | $10.05 | −$221.1K | −2.0%1.08M after | 10b5-1 |
| Apr 7, 2026 (view filing) | Apr 6 | 1 day | De Backer MariannePresident and CEO | SSale | −72.6K | $9.16 | −$664.6K | −7.1%948.1K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Sato Vicki LDirector | SSale | −22.0K | $9.07 | −$199.5K | −2.0%1.10M after | 10b5-1 |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Sabatini BrentSVP, Chief Accounting Officer | SSale | −7.71K | $9.12 | −$70.3K | −11.1%61.9K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Sato Vicki LDirector | SSale | −22.0K | $9.50 | −$209.1K | −1.9%1.12M after | 2 lots10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Sato Vicki LDirector | SSale | −42.4K | $9.75 | −$413.3K | −3.6%1.14M after | 2 lots10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Sabatini BrentSVP, Chief Accounting Officer | SSale | −1.43K | $9.53 | −$13.6K | −2.0%69.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 237 holdersThe largest institutional positions in Vir Biotechnology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,678,283 | $210.7M | 0.00% | +2,679,954+14.9% | Added |
| ARCH Venture Management, LLC | 12,694,163 | $129.4M | 11.76% | −222,500−1.7% | Reduced |
| Vanguard Portfolio Management LLC | 11,495,215 | $117.1M | 0.01% | +2,279,638+24.7% | Added |
| SB Investment Advisers (UK) Ltd | 10,948,093 | $111.6M | 1.46% | 00.0% | Unchanged |
| State Street Corp | 9,964,151 | $101.5M | 0.00% | +2,823,057+39.5% | Added |
| GSK plc | 8,550,954 | $87.1M | 14.47% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 6,388,775 | $65.1M | 0.00% | +1,006,672+18.7% | Added |
| Point72 Asset Management, L.P. | 5,666,821 | $57.7M | 0.09% | +3,714,587+190.3% | Added |
| Geode Capital Management, LLC | 3,348,366 | $34.1M | 0.00% | +690,523+26.0% | Added |
| Dimensional Fund Advisors LP | 3,119,421 | $31.8M | 0.01% | +539,743+20.9% | Added |
Holders of 5% or more of VIR
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vir Biotechnology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 12.40%20.9M shares | +1.60 ppfrom 10.80% | Apr 28, 20252 filings | Oct 27, 2026 | SEC |
| ARCH Venture Fund IX, L.P. | 13D/A | 7.30%12.5M shares | −1.20 ppfrom 8.50% | Apr 14, 20217 filings | Nov 6, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G/A | 6.85%11.6M shares | +1.06 ppfrom 5.79% | Apr 29, 20262 filings | Jul 31, 2026 | SEC |
| SB Investment Advisers (UK) Ltd | 13G/A | 6.50%10.9M shares | −2.90 ppfrom 9.40% | Feb 13, 20243 filings | May 15, 2026 | SEC |